Trifluoromescaline (TFM), also known as 4-(trifluoromethoxy)-3,5-dimethoxyphenethylamine, is a derivative of the phenethylamine psychedelic mescaline, which has a 4-trifluoromethoxy group replacing the 4-methoxy group of mescaline. It was found to be one of the most potent compounds in the scaline series, with a reported dose of 15 to 40mg (and 60mg being described as a "strong overdose"), and a slow onset of action and long duration of effects, lasting 14 to 24hours or more. The drug showed about 36-fold greater activational potency at the serotonin 5-HT<sub>2A</sub> receptor compared to mescaline in vitro. In addition, it appears to be much more lipophilic than mescaline (predicted log P = 1.9 vs. 0.7, respectively). TFM was first described in the scientific literature by Daniel Trachsel by 2012. Many other related compounds have also been described by Trachsel and colleagues. It is not a controlled substance in Canada as of 2025.